Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 14:2022:1832241.
doi: 10.1155/2022/1832241. eCollection 2022.

The Protective Mechanism of Afuresertib against Esophageal Cancer

Bo Min  1 , Yan Wang  1 , Feng Liang  2 , Cheng-Xiang Wang  1 , Fan Wang  1 , Zhi Yang  3
Affiliations

The Protective Mechanism of Afuresertib against Esophageal Cancer

Bo Min et al. Dis Markers. .

Abstract

Esophageal cancer (EC) is a common malignant tumor of the digestive system. Exploring the molecular biological mechanism of EC will help to clarify its carcinogenesis mechanism, find important molecular targets in the process of carcinogenesis, and provide new ideas for the diagnosis and treatment of EC. Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signaling pathway is one of the signal transduction pathways most closely related to cell proliferation and apoptosis. The regulation of various downstream molecules affects the proliferation and growth of tumor cells. In this study, we determined the effect of different concentrations of afuresertib on cell viability by MTT assay and determined the effect of afuresertib on cell apoptosis by Annexin V-FITC/PI dual staining. Animal experiments verified the effects of afuresertib on VEGF, bFGF, and PI3K/Akt. Our results indicated that afuresertib is closely related to the survival, proliferation, and apoptosis of esophageal cancer cell lines. More importantly, we found that afuresertib could reduce tumor volume and mass in EC rats through in vivo experiments. In conclusion, afuresertib may exert its antitumor effect by inhibiting the expression of PI3K and Akt-related proteins in rat tumor tissues.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
The effect of different concentrations of afuresertib on the viability of Eca109 cells.
Figure 2
Figure 2
The effect of different concentrations of afuresertib on the OD value of Eca109 cells.
Figure 3
Figure 3
Effects of afuresertib on apoptosis of Eca109 cells. Flow cytometry with Annexin V-FITC/PI dual staining of Eca109 cells treated with increasing concentrations of afuresertib.
Figure 4
Figure 4
Expression of apoptosis-related proteins and genes in Eca109 cells. (a) Bax, Bcl-2, and Caspase-3 grayscale values. (b) Relative mRNA expression of Bax, Bcl-2, and Caspase-3.
Figure 5
Figure 5
The effect of afuresertib on the expression of VEGF and bFGF protein in rat tumor tissue. (a) Protein grayscale values. (b) Relative protein expression levels. Note: A, B, and C represent the comparison with the model group, the low-dose group, and the middle-dose group, P < 0.05.
Figure 6
Figure 6
The effect of afuresertib on PI3K and Akt proteins in rat tumor tissue. (a) Protein grayscale values. (b) Relative protein expression levels. Note: A, B, and C represent the comparison with the model group, the low-dose group, and the middle-dose group, P < 0.05.
See this image and copyright information in PMC

References

    1. Thrumurthy S. G., Chaudry M. A., Thrumurthy S. S. D., Mughal M. Oesophageal cancer: risks, prevention, and diagnosis. BMJ . 2019;366, article l4373 - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Merkow R. P., Bilimoria K. Y., Keswani R. N., et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. Journal of the National Cancer Institute . 2014;106(7):p. dju133. doi: 10.1093/jnci/dju133. - DOI - PubMed
    1. Anderegg M. C. J., Ruurda J. P., Gisbertz S. S., et al. Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma. European Journal of Surgical Oncology . 2020;46(4):626–631. doi: 10.1016/j.ejso.2019.10.023. - DOI - PubMed
    1. Tian J., Mei X., Guo M., Xiong R., Sun X. Effectiveness of jejunostomy for enteral nutrition during complete thoracoscopic and laparoscopic Ivor-Lewis esophagectomy in thoracic segment esophageal carcinoma. Journal of Cardiothoracic Surgery . 2020;15(1):p. 142. doi: 10.1186/s13019-020-01162-7. - DOI - PMC - PubMed

LinkOut - more resources